233 related articles for article (PubMed ID: 21928286)
1. An evidential approach to non-inferiority clinical trials.
Wang SJ; Blume JD
Pharm Stat; 2011; 10(5):440-7. PubMed ID: 21928286
[TBL] [Abstract][Full Text] [Related]
2. Designing a non-inferiority study in kidney transplantation: a case study.
Witte S; Schmidli H; O'Hagan A; Racine A
Pharm Stat; 2011; 10(5):427-32. PubMed ID: 21928323
[TBL] [Abstract][Full Text] [Related]
3. The ABC of non-inferiority margin setting from indirect comparisons.
Julious SA
Pharm Stat; 2011; 10(5):448-53. PubMed ID: 21928354
[TBL] [Abstract][Full Text] [Related]
4. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
D'Agostino RB; Massaro JM; Sullivan LM
Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
[TBL] [Abstract][Full Text] [Related]
5. [Reduction of haemorrhagic risk in acute coronary syndromes].
Merino A; Roldán I; Marín F; Worner F;
Med Clin (Barc); 2011 Nov; 137(14):650-5. PubMed ID: 20701931
[No Abstract] [Full Text] [Related]
6. The network meta-analytic-predictive approach to non-inferiority trials.
Schmidli H; Wandel S; Neuenschwander B
Stat Methods Med Res; 2013 Apr; 22(2):219-40. PubMed ID: 22218367
[TBL] [Abstract][Full Text] [Related]
7. On non-inferiority margin and statistical tests in active control trials.
Chow SC; Shao J
Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
[TBL] [Abstract][Full Text] [Related]
8. Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.
Koopmeiners JS; Hobbs BP
Stat Methods Med Res; 2018 May; 27(5):1547-1558. PubMed ID: 27587591
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Danchin N; Aïssaoui N
Cardiovasc Drugs Ther; 2010 Aug; 24(4):325-30. PubMed ID: 20714797
[TBL] [Abstract][Full Text] [Related]
10. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
[TBL] [Abstract][Full Text] [Related]
11. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
Mehran R; Nikolsky E; Lansky AJ; Kirtane AJ; Kim YH; Feit F; Manoukian S; Moses JW; Ebrahimi R; Ohman EM; White HD; Pocock SJ; Dangas GD; Stone GW
JACC Cardiovasc Interv; 2009 Aug; 2(8):748-57. PubMed ID: 19695543
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Nikolsky E; McLaurin BT; Cox DA; Manoukian SV; Xu K; Mehran R; Stone GW
JACC Cardiovasc Interv; 2012 Sep; 5(9):919-26. PubMed ID: 22995879
[TBL] [Abstract][Full Text] [Related]
14. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
15. Challenges and regulatory experiences with non-inferiority trial design without placebo arm.
Hung HM; Wang SJ; O'Neill R
Biom J; 2009 Apr; 51(2):324-34. PubMed ID: 19358213
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin.
Warkentin TE; Greinacher A; Koster A
Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
18. Adaptive non-inferiority margins under observable non-constancy.
Hanscom B; Hughes JP; Williamson BD; Donnell D
Stat Methods Med Res; 2019; 28(10-11):3318-3332. PubMed ID: 30293490
[TBL] [Abstract][Full Text] [Related]
19. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Rubboli A; Halperin JL
Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
[No Abstract] [Full Text] [Related]
20. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
